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Abstract
Background: The combination of blue dye and radioisotope is most widely used to identify sentinel lymph nodes
(SLNs) in patients with breast cancer. However, some individual studies suggested that dual tracers did not have an
advantage over radioisotope alone in detecting SLNs. We performed a systematic review to investigate the added
value of blue dye in addition to radioisotope.
Methods: We searched Pubmed and Embase. Prospective studies that compared the combination of radioisotope
and blue dye with radioisotope alone were selected. The identification rate of SLNs and the false-negative rate
were the main outcomes of interest. The odds ratios (ORs) and 95 % confidential intervals (CIs) were calculated by
using random-effects model.
Results: Twenty-four studies were included. The combination of radioisotope and blue dye showed higher identification
rate than radioisotope alone (OR = 2.03, 95 % CI 1.53–2.69, P < 0.05). However, no statistically significant difference was
revealed for patients after neoadjuvant chemotherapy (OR = 1.64, 95 % CI 0.82–3.27, P > 0.05), or for studies with high
proportion of patients with positive lymphoscintigraphy (OR = 1.41, 95 % CI 0.83–2.39, P > 0.05). Dual tracers did not
significantly lower the false-negative rate compared with radioisotope alone (OR = 0.76, 95 % CI 0.44–1.29, P > 0.05).
Conclusions: Although the combination of blue dye and radioisotope outperformed radioisotope alone in SLN
detection, the superiority for dual tracers may be limited for patients with positive lymphoscintigraphy or for those after
neoadjuvant chemotherapy. Besides, the combined modality did not help lower the false-negative rate.
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Background
The most important prognostic factor for patients with
early-stage breast cancer was the disease status of axillary
lymph nodes [1]. Recently, sentinel lymph node biopsy
(SLNB) has replaced axillary lymph node dissection
(ALND) to be the standard procedure for axillary staging in
patients with clinically node-negative breast cancer [2, 3].
SLNs were defined as the first lymph nodes that received
lymphatic drainage from the primary cancer. Since the early
1990s, blue dye and radioisotope have emerged as the most
commonly used tracing agents to locate SLNs in breast
cancer [4, 5]. In particular, the combined use of blue dye
and radioisotope gained widespread popularity [6]. A previ-
ous survey of fellows of the American College of Surgeons
showed that 90 % used the combined modality [7].
Notably, blue dye injection carried the potential risks of
skin tattooing, skin necrosis, and allergic reactions [8].
Approximately 2 % of patients undergoing SLNB would
experience allergic reactions to blue dye [9], with the most
severe case presenting as hypotension [10]. Several authors
argued that the added value of blue dye over radiotracer
alone technique was only minimal or marginal [9–11]. The
results from a large case series suggested that the marginal
benefit for blue dye declined with increased surgical experi-
ence in radioisotope-mapping technique [12].
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It is attractive to use radioisotope alone to avoid the
blue-dye complications and lower the cost of hospital
care. However, the current knowledge on the added
value of blue dye is still based on weak evidence from
scattered individual studies without universal consensus.
A randomized controlled trial (RCT) has only recently been
conducted to compare dual tracers with radioisotope alone
in patients before neoadjuvant chemotherapy (NAC) with
positive preoperative lymphoscintigraphy (LSG), which
demonstrated no advantage for dual tracers in SLN detec-
tion [11]. The authors speculated that the blue dye should
be added only for patients with negative LSG or those
having received NAC. An evidence-based systematic review
was warranted to identify patients who will particularly
benefit from dual tracers, and to help inform SLNB
decision-making. Thus, we conducted this systematic
review regarding prospective studies on SLNB in breast
cancer, aiming to gain a better understanding of the incre-
mental value of blue dye in addition to radioisotope. Espe-




Electronic databases of Pubmed and Embase were system-
atically searched up to June 2015. The search terms used
were: ‘sentinel lymph node’, ‘breast cancer’, ‘blue dye’ or
‘lymphazurin’ or ‘Isosulfan’ or ‘methylene blue’ or ‘patent
blue’, ‘isotope’ or ‘radioisotope’ or ‘radiolabeled colloid’ or
‘radiocolloid’ or ‘radiotracer’. The search was restricted to
human subjects and English language. All studies were
critically appraised for inclusion eligibility. We also manu-
ally searched the reference lists of relevant studies.
Inclusion criteria
Studies were considered for inclusion if they fulfilled the
following criteria: (1) reported the use of blue dye and
radioisotope for SNLB in female breast cancer patients;
(2) showed the comparison between the combination of
blue dye and radioisotope with radioisotope alone; (3)
reported outcomes of the identification rate of SLNs or
the false-negative rate; (4) prospectively collected patients’
data, designed as randomized controlled trial (RCT) or
non-randomized prospective study (NPS); (5) enrolled at
least 100 patients, with at least 20 patients available for
each mapping strategy.
Data extraction and quality assessment
Data from the included studies were extracted independ-
ently by two authors (PSH and GHL). Any discrepancy
was resolved by consensus or by discussion with a third au-
thor (FL). The following information was extracted: author
and publication year, location, study design, sample size,
age, clinical status of axillary nodes, NAC use, mapping
materials, injection site, and proportion of patients with
positive preoperative LSG. The identification rate of SLNs
and the false-negative rate were directly extracted or indir-
ectly calculated for each mapping strategy. The quality of
studies were appraised by a revised 6-item scale which was
derived from a previous 5-item scale [13]. Assuming that
the success rate of SLN identification reached the level of
98 % for dual mapping agents, and differed by 5 % between
dual and single tracing agents, accompanied by a Type I
error probability for a two-sided test of 5 % and statistical
power of 80 %, the required sample size in each group was
calculated to be approximately 300 [14]. Thus, we listed
the sufficiency of sample size as one item on the quality
scale. The quality assessment included the following ele-
ments: 1) describing patients’ characteristics, 2) explaining
reasons for withdrawal, 3) describing measures of out-
comes, 4) incorporating measures of confounding factors,
5) describing the SLN technique (mapping material and
injection site), and 6) enrolling at least 300 patients. The
study with 5 points or more was regarded as high quality.
Statistical analysis
The odds ratios (ORs) and 95 % confidential intervals
(CIs) were used as statistical measures for dichotomous
outcomes. They were calculated from the number of
patients in each mapping modality. The identification rate
of SLNs and the false-negative rate were considered as the
main outcomes. The random-effects model was used to
calculate the summary effect estimates [15]. The hetero-
geneity between studies was analyzed by the I2 statistics
and Cochrane Q test, with I2 > 50 % and P < 0.05 deemed
as significant heterogeneity. The source of heterogeneity
was explored by subgroup analysis, meta-regression and
cumulative analysis. The following predefined covariates
were considered into subgroup analyses: clinical node sta-
tus (negative or positive), NAC use (before NAC or after
NAC), proportion of patients with positive preoperative
LSG (≥90 % or < 90 %), sample size (>300 or <300), data
source (RCT or NPS), and injection site of mapping mate-
rials (superficial or deep). The superficial injection sites
included periareolar, subareolar, intradermal, and subder-
mal; the deep injection sites included peritumoral, intratu-
moral, and intraparenchymal [16]. Meta-regression
analysis was performed according to the sample size, pub-
lication year, and the proportion of patients with positive
preoperative LSG. The cumulative analysis was conducted
according to the publication year. The publication bias
was examined visually by the funnel plot and statistically
by the Egger’s test. P < 0.05 was considered to represent
statistically significance. The statistical analyses were per-
formed by the STATA 12.0 (StataCorp LP, College Station,
Texas, USA).
Additionally, we pooled the false-negative rates and
the incidence of adverse reactions caused mapping agents,
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which were processed by the software of Comprehensive
Meta-Analysis statistical package (CMA Version 2.2,




A total of 309 citations were identified after the initial
search, including 137 citations from Embase and 172 cita-
tions from Pubmed. Sixty-one duplicated records were
excluded. Then we excluded reviews, case reports, edito-
rials, studies with small sample sizes (<100), and studies of
irrelevant topics. Seventy-four studies were screened by
titles and abstracts. After excluding 26 retrospective studies,
the full-texts of 48 records were assessed for eligibility. Data
on the combined mapping modality could not be obtained
from 12 studies. Twelve studies enrolled patients of the
duplicated cohorts. Finally, twenty-four studies were se-
lected for meta-analyses [1, 3, 8, 10–12, 17–34]. The flow
diagram of selection process was depicted in Fig. 1.
Study characteristics and quality assessment
A total of 15,462 patients with breast cancer undergoing
SLNB were involved. The characteristics of 24 included
studies were presented in Table 1. The sample size
ranged from 100 to 3402, with 15 studies of sample sizes
over 300 and 9 studies of sample sizes below 300. Eight
studies were conducted in the United States, 11 in
Europe, and 5 in Asia. Six studies were designed as
RCTs. However, only one RCT was primarily designed
Fig. 1 The flow diagram of literature search process
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to compare radioisotope alone with the combined use of
radioisotope and blue dye [11]. The comparison data
were retrieved from post-hoc analyses for other five RCTs.
Eighteen studies were non-randomized prospective stud-
ies. The study qualities were appraised by the revised 6-
item scale. The overall assessment was satisfactory with all
scores ranging from 3 to 6. Most studies clearly described
the patients’ characteristics (21/24), the details of SLN
procedures (20/24), the confounding factors (21/24), and
the measures of outcomes (24/24). However, the explan-
ation of withdrawal or the selection process of participants
were clearly stated by only few studies (7/24). The quality
assessment was shown in Table 2.
Identification rate of SLNs
All of the 24 studies compared the the identification rate
of SLNs between dual tracers and radioisotope alone.
The pooled results demonstrated that the combined use
of radioisotope and blue dye had higher identification
rate of SLNs than radioisotope alone (OR = 2.03, 95 % CI
1.53–2.69, P < 0.05) (Fig. 2). Significant heterogeneity was
detected (I2 = 64.9 %, P < 0.05). The primary subgroup ana-
lyses were conducted according to the clinical node status,
NAC use (before NAC or after NAC), and proportion of
patients with positive preoperative LSG (≥90 % or < 90 %).
The impact of clinical node status
The clinical axillary node status was exclusively negative
in 14 studies, exclusively positive in 1 study, mixed in 4
studies, and not clear in 4 studies (Table 1). In the sub-
group of 14 studies with clinically node-negative breast
cancer, the pooled data indicated that the use of dual
tracers was superior to radioisotope alone in identifying
SLNs (OR = 2.56, 95 % CI 1.88–3.49, P < 0.05; I2 = 48.7 %).
However, no significant results were revealed for other
subgroups (Table 3).
The impact of neoadjuvant chemotherapy
The use of NAC was clearly described by 8 studies, includ-
ing 5 studies of patients before NAC, 2 studies of patients
after NAC, and 2 studies with mixed populations (Table 1).
Kuehn et al. reported both data for patients before NAC
and those after NAC, which were extracted separately [3].
For 6 studies including patients before NAC [1, 3, 11, 21,
31, 34], the combined use of blue dye and radioisotope
showed higher identification rate than radioisotope alone
(OR = 2.96, 95 % CI 1.78–4.94, P < 0.05; I2 = 15.6 %). For 3
studies including patients after NAC [3, 20, 27], no statisti-
cally significant difference was revealed when comparing
dual tracers with radioisotope alone (OR = 1.53, 95 % CI
0.94–2.47, P > 0.05; I2 = 31.6 %) (Table 3).
The impact of preoperative LSG
The proportion of patients with positive preoperative LSG
was reported by 13 studies, ranging from 69.3 to 100 %
(Table 1). For 7 studies with a high proportion (≥90 %) [1,
3, 10, 11, 25, 29, 30], the pooled data revealed no statisti-
cally significant difference between dual tracers and radio-
isotope alone (OR = 1.41, 95 % CI 0.83–2.39, P > 0.05).
For 6 studies with a relatively low proportion (<90 %)
[19, 21–23, 26, 31], the advantage of using dual
tracers was statistically significant (OR = 2.99, 95 % CI
1.99–4.48, P > 0.05) (Table 3).
Stratified analyses
Additionally, subgroup analyses were conducted according
to the data source (RCT or NPS), sample size (over 300 or
below 300), location (USA, Europe, or Asia), injection site
of blue dye (superficial or deep), and injection site of
radioisotope (superficial or deep). Three studies used both
superficial injection and deep injection [19, 22, 31].
Related data were extracted separately. The results
remained significant in most subgroup analyses. However,
no statistically significant difference was shown between
dual tracers and radioisotope alone for patients receiv-
ing superficial injection of blue dye (OR = 1.95, 95 % CI
0.93–4.08, P > 0.05), or for those receiving superficial
injection of radioisotope (OR = 2.05, 95 % CI 0.87–4.84,
P > 0.05). Results for subgroup analyses were summa-
rized in Table 3.
Meta-regression and cumulative analysis
The publication year and sample size were considered as
independent variables into meta-regression analyses. No
significant independent effect was detected for publication
year (P = 0.37) or sample size (P = 0.52). Meta-regression
was also performed for 13 studies reporting the proportion
of patients with preoperative LSG, which showed a signifi-
cant independent effect of this covariate (P < 0.01). As-
sumed that the surgical experience in mapping techniques
increased over years, cumulative analysis was performed to
investigate the effect of publication year. Notably, the ad-
vantage of combined mapping modality was stable over
years (Fig. 3).
Publication bias
The funnel plot was visually symmetrical (Fig. 4). No stat-
istical significance was detected by Egger’s test (P = 0.34).
False-negative rate
The false-negative rate was investigated by 12 studies
[1, 3, 17, 18, 20, 22–27, 32]. The pooled false-
negative rate was 7.5 % (95 % CI 4.8–11.5 %), with
significant heterogeneity (I2 = 82.4 %, P < 0.05) (Fig. 5a).
However, only 4 studies reported the comparison of
false-negative rate between radioisotope alone and the
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Table 1 Characteristics of included studies




NAC use Radioisotope type Blue dye type Site of Blue dye Site of isotope Positive Preo
LSG, No. (%)
Bass et al. (1999)
[18]
NPS USA 700 58 Unknown Unknown Filtered 99mTc-sulfur
colloid
Isosulfan Intraparenchymal Intraparenchymal Unknown
Mariani et al. (2000)
[28]
NPS Italy 284 59 Mixed Unknown 99mTc-human
albumin
Patent blue Subdermal Subdermal Unknown
Rahusen et al.
(2000) [30]
NPS Netherlands 115 54 Unknown Unknown 99mTc-human
albumin
Patent blue intradermal Intraparenchymal 105/115 (91 %)
Derossis et al.
(2001) [12]
NPS USA 2000 Unknown Negative Unknown Unfiltered 99mTc-
sulfur colloid
Isosulfan Intraparenchymal Intradermal Unknown
Bauer et al. (2002)
[19]




Peritumoral 195/223 (87.4 %)
Ahrendt et al.
(2002) [17]
NPS USA 174 59 Negative Unknown Filtered 99mTc-sulfur
colloid
Isosulfan Intraparenchymal Intraparenchymal Unknown
Tsunoda et al.
(2002) [34]





Pelosi et al. (2003)
[29]




Periareolar or subdermal 93/100 (93 %)
Fleming et al.
(2003) [22]





NPS Germany 814 58 62.9 %
negative





NPS Denmark 124 56 Negative Unknown 99mTc-human
albumin
Patent blue Peritumoral Peritumoral Unknown
Mamounas et al.
(2005) [27]
RCT USA 428 Unknown 76.2 %
negative
Yes Unknown Isosulfan Unknown Unknown Unknown
Takei et al. (2006)
[33]
NPS Japan 308 55 Negative Unknown 99mTc-phytate Patent blue Subdermal Subdermal Unknown
Argon et al. (2006)
[1]
NPS Turkey 100 48 Negative No 99mTc-tin colloid Isosulfan Intraparenchymal Intradermal 90/100 (90 %)
Low et al. (2006)
[26]
NPS Australia 113 56 Negative Unknown 99mTc-sulfur colloid Patent blue Intradermal or
subdermal
Peritumoral 97/113 (85.8 %)
Goyal et al. (2006)
[23]
RCT UK 842 18–80 Negative Unknown 99mTc-albumin
colloid
Patent blue Peritumoral Peritumoral 490/707 (69.3 %)
Lelievre et al. (2007)
[25]





Rodier et al. (2007)
[31]





Kang et al. (2010)
[10]
NPS USA 3402 56 Negative Mixed 99mTc-sulfur colloid Isosulfan Unknown Unknown 1566/1720
(91.0 %)

























RCT USA 689 49 (23–
93)





RCT Australia 1088 Unknown Negative No 99mTc-sulfur colloid Patent blue Peritumoural Peritumoural 779/957 (81.4 %)
O'Reilly et al. (2015)
[11]
RCT Ireland 667 48 Negative No Unknown Isosulfan Intradermal Subdermal 667/667 (100 %)












combined method [3, 20, 27, 32]. Kuehn et al. re-
ported the false-negative rate in two subgroups, and
they were separately analyzed [3]. The combined use
of radioisotope and blue dye did not significantly
lower the false-negative rate when compared with radio-
isotope alone (OR =0.76, 95 % CI 0.44–1.29, P > 0.05). No
Table 2 Quality assessment of included studies by a revised 6-item scale


















0 0 1 1 1 1 4
Mariani et al.
(2000) [28]
1 0 1 0 1 0 3
Rahusen et al.
(2000) [30]
1 0 1 0 1 0 3
Derossis et al.
(2001) [12]
1 0 1 1 1 1 5
Bauer et al.
(2002) [19]
1 0 1 1 1 1 5
Pelosi et al.
(2003) [29]
1 0 1 1 1 0 4
Fleming et al.
(2003) [22]
1 0 1 1 1 0 4
Ahrendt et al.
(2002) [17]
1 0 1 1 1 0 4
Tsunoda et al.
(2002) [34]
0 0 1 1 1 1 4
Schirrmeister
et al. (2004) [32]
1 0 1 0 0 1 3
Lauridsen et al.
(2004) [24]
1 1 1 1 1 0 5
Mamounas et al.
(2005) [27]
1 1 1 1 0 1 5
Takei et al.
(2006) [33]
1 0 1 1 1 1 5
Argon et al.
(2006) [1]
1 0 1 1 1 0 4
Low et al.
(2006) [26]
1 1 1 1 1 0 5
Goyal et al.
(2006) [23]
1 0 1 1 1 1 5
Lelievre et al.
(2007) [25]
1 0 1 1 1 0 4
Rodier et al.
(2007) [31]
1 1 1 1 1 1 6
Kang et al.
(2010) [10]
1 0 1 1 0 1 4
Johnson et al.
(2011) [8]
0 0 1 1 1 1 4
Kuehn et al.
(2013) [3]
1 1 1 1 0 1 5
Elmadahm et al.
(2015) [21]
1 0 1 1 1 1 5
O'Reilly et al.
(2015) [11]
1 1 1 1 1 1 6
Boughey et al.
(2013) [20]
1 1 1 1 1 1 6
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significant heterogeneity was detected (I2 = 21.0 %,
P > 0.05) (Fig. 5b).
Adverse reactions
Of the 24 publications, no study reported adverse epi-
sodes for the use of radioisotope. In contrast, 4
studies reported allergic reactions to blue dye [1, 10,
11, 21]. Most patients experienced mild allergic reac-
tions. However, Kang et al. reported 5 cases of serious
allergic reactions presenting as hypotension among
2049 patients [10]. The pooled incidence of allergic
reaction to blue dye was 0.6 % (95 % CI 0.2–1.7 %),
Fig. 2 Forest plot showing that the combined use of blue dye and radioisotope showed higher SLN identification rate than radioisotope alone
Fig. 3 Cumulative meta-analysis according to the publication year showing that the advantage of dual tracers remained stable over years
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with significant heterogeneity (I2 = 72.5 %, P < 0.05)
(Fig. 6).
Discussion
This systematic review included 24 studies involving
15,462 participants. To our knowledge, it represented
the largest and most comprehensive systematic review of
prospective studies investigating the added value of blue
dye in addition to radioisotope alone for tracing SLNs in
breast cancer. It reflected the worldwide experience over
20 years. The overall pooled analysis showed that the
combination of radioisotope and blue dye was superior
to radioisotope alone for the successful identification of
SLNs. The pooled false-negative rate was 7.5 %, which
was similar to the pooled rate of 7.3 % in a previous
meta-analysis [13]. Notably, the combined use of blue
dye and radioisotope failed to confer significant advan-
tage in lowering the false-negative rate.
The recent RCT failed to demonstrate an advantage
with the addition of blue dye to radioisotope alone in
Table 3 Subgroup analyses of studies on the sentinel lymph node identification
Subgroups No. of studies OR 95 % CI P value Heterogeneity (I2)
Clinical node status
Negative 14 2.56 1.88–3.49 <0.05 48.7
Positive 1 1.42 0.68–2.96 >0.05 –
Mixed 4 1.93 0.99–3.76 >0.05 59.5
NAC
Before NAC 6 2.96 1.78–4.94 <0.05 15.6
After NAC 3 1.53 0.94–2.47 >0.05 31.6
Proportion of patients with positive LSG
≥ 90 % 7 1.41 0.83–2.39 >0.05 22.1
< 90 % 6 2.99 1.99–4.48 <0.05 42.8
Data source
RCT 6 2.25 1.23–4.11 <0.05 74.7 %
NPS 18 1.96 1.40–2.74 <0.05 62.5 %
Sample size
> 300 15 2.01 1.42–2.84 <0.05 75.9 %
< 300 9 2.01 1.28–3.15 <0.05 7.0 %
Location
USA 8 1.33 0.82–2.16 >0.05 80.1 %
Europe 11 2.48 1.60–3.84 <0.05 43.7 %
Asia 5 2.93 2.05–4.19 <0.05 1.3 %
Injection site of blue dye
Superficial 10 1.95 0.93–4.08 >0.05 70.6 %
Deep 9 2.76 2.32–3.30 <0.05 0
Injection site of radioisotope
Superficial 9 2.05 0.87–4.84 >0.05 76.0 %
Deep 11 2.55 1.93–3.37 <0.05 31.2 %
LSG lymphoscintigraphy, NAC neoadjuvant chemotherapy
Fig. 4 Funnel plot showing that no evidence of publication bias
was identified
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patients before NAC with positive preoperative LSG
[11]. LSG is a useful tool to establish abnormal lymph-
atic drainage patterns, and to detect extra-axillary nodes
particularly internal mammary nodes [21, 24, 30]. It is
an integral part of single radioisotope tracer during
SLNB. Half of our included studies have performed
preoperative LSG. When pooling results for studies
enrolling over 90 % patients with positive LSG, no
advantage was demonstrated for using dual tracers.
Meta-regression analysis revealed that preoperative LSG
appeared to be the source of heterogeneity. These results
were consistent with the recent trial that positive pre-
operative LSG may preclude the additional use of blue
dye [11]. Several studies have suggested that the uptake
of radioisotope was less favorable after NAC compared
with primary surgery, which may decrease the detection
rate of SLNs [3, 35, 36]. Nevertheless, we failed to show
the advantage of dual tracers for patients after NAC.
Additionally, the statistical significance was not shown
in the subgroups of superficial injection of blue dye or
radioisotope. For a long time, the optimal injection sites
of mapping agents were controversial. A previous meta-
analysis suggested that both superficial and deep injections
of radioisotope and blue dye were effective for identifying
Fig. 5 Forest plots showing the pooled false-negative rate, and the comparison between dual tracers and radioisotope alone in false-negative
rate. a pooled false-negative rate b Forest plot of ORs showing that the combination of blue dye and radioisotope did not significantly decrease
the false-negative rate when compared with radioisotope alone
Fig. 6 Forest plot showing the pooled incidence of allergic reaction
to blue dye
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SLNs, but failing to show statistical difference between the
two methods [16]. Interestingly, in 3 studies comparing
superficial injection with deep injection, the blue and hot
concordance was higher in the superficial-injection group
compared with the deep-injection group (90 % versus
87 %, 95.5 % versus 85.5 %, and 95.6 % versus 91.5 %,
respectively) [19, 22, 31]. Thus, we inferred that the high
concordance of blue dye and radioisotope for superficial
injection may weaken the additional value of blue dye.
The learning curve was associated with the successful
rate of SLN identification. It was estimated that 23
patients were required by an individual surgeon to
achieve a 90 % ± 4.5 % success rate and 53 patients were
required to achieve a 95 % ± 2.3 % success rate [18]. The
marginal benefit of blue dye was shown to be significant
during the initial learning period, but declining with
increased experience in using radioisotope alone [10, 12].
Assuming that breast surgeons have gained more experi-
ence in mapping techniques during the recent years,
cumulative and meta-regression analyses were conducted
according to the publication year. However, no statistical
significance was detected.
One major concern for blue dye was the potential risk
of complications, which were infrequent but significant,
including anaphylaxis, skin tattooing, and skin necrosis at
the injection site [8]. Our results showed that the inci-
dence of allergic reaction to blue dye was at a low level of
0.6 %. The allergic reactions to blue dye were categorized
into grade 1 (urticaria or blue hives, pruritis, or a general-
ized rash), grade 2 (hypotension not requiring vasopres-
sors), or grade 3 (hypotension requiring pressor support)
[37]. Most allergic episodes in our included studies were
of grade 1, and only Kang et al. reported the hypotension
episodes of grade 2 (5/2049) and grade 3 (2/2049) [10]. In
addition, blue dye may be unavailable in some institutions
due to nationwide shortage. The localization of SLNs was
surgeon-dependent for mapping with blue dye [18].
Although the cost of methylene blue was low, the charge
for lymphazurin reached as high as approximately $600 in
the USA [8]. Thus, the conversion from dual tracers to a
single radioisotope injection would help facilitate the
biopsy procedure, reduce complications, and diminished
cost as well as resource utilization.
Several limitations of our study should be acknowledged.
The number of included studies was small for the outcome
of false-negative rate. Only a minority of the selected stud-
ies recorded the events of allergic reactions to blue dye in
follow-up. Especially, only 1 RCT was primarily designed to
compare dual tracers with radioisotope alone [11]. Most
studies were non-randomized studies or post-hoc analyses
of RCTs. The reason for choice of tracer was unknown for
most studies. Thus, the selection bias may exist. It was
difficult to match the age, race, distribution of clinical
stages, relation to NAC, type of radiotracer, injection site of
mapping agents, and surgeons’ experience between the
comparison groups. These confounding factors may affect
the identification rate as well as the false-negative rate.
Skip metastasis, intraoperative pathological technique,
and lymphatic vessel obstruction have been suggested to
the main reasons for false-negative results [38], which
may overweigh the influence of mapping-agents choice.
Conclusion
In conclusion, compared with radioisotope alone, blue dye
plus radioisotope showed a higher success rate of SLN
identification. Nevertheless, the added value of blue dye
appeared to be limited for patients with positive preopera-
tive LSG, having received NAC, or undergoing superficial
injection of tracing agents. Dual tracers were unhelpful for
lowering the false-negative rate of SLNs. Considering the
adverse reactions and inconvenience caused by blue dye
injection, and the increased experience in using radioiso-
tope, the advantage of dual tracers over radioisotope alone
may be overestimated. Further well-designed randomized
studies are required to recognize the sub-population in
whom the dual tracers is especially required.
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